EUROPEAN: bourses were all down significantly in the reporting period to February 11, with particularly heavy falls on February 5 on the back of Wall Street's plunge, having had a relatively positive previous week. Pharmaceutical stocks generally followed the negative trend. In FRANKFURT, there was an across-the-board decline, with MorphoSys dropping 5.9% after its recent strong advances, and drug majors Bayer and Merck KGaA falling 1.3% and 2.9%, respectively. PARIS saw a 4.3% decline in Sanofi-Aventis, but the stock outperformed the CAC 40's 5.8% drop, ahead of reporting 2007 financial results (see page 5), following which it put on a 2.4% gain. On the AMSTERDAM stock exchange, the worst performer was Crucell, which fell 7.0%, despite the firm announcing a reduction in its fourth-quarter 2007 loss (see page 10). ZURICH saw declines of 4.1% and 1.1%, respectively, for drug majors Roche and Novartis, while Speedel gained 2.8% on no particular news since its downgrade last month by JP Morgan analysts.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
A Nasdaq-listed biopharmaceutical company developing small-molecule medicines for cardiovascular, metabolic and neurological diseases. Lexicon Pharmaceuticals focuses on therapies discovered through genetic and molecular research designed to address serious chronic conditions.
Stock Commentary - Europe - week to Feb 11, 2008
EUROPEAN: bourses were all down significantly in the reporting period to February 11, with particularly heavy falls on February 5 on the back of Wall Street's plunge, having had a relatively positive previous week. Pharmaceutical stocks generally followed the negative trend. In FRANKFURT, there was an across-the-board decline, with MorphoSys dropping 5.9% after its recent strong advances, and drug majors Bayer and Merck KGaA falling 1.3% and 2.9%, respectively. PARIS saw a 4.3% decline in Sanofi-Aventis, but the stock outperformed the CAC 40's 5.8% drop, ahead of reporting 2007 financial results (see page 5), following which it put on a 2.4% gain. On the AMSTERDAM stock exchange, the worst performer was Crucell, which fell 7.0%, despite the firm announcing a reduction in its fourth-quarter 2007 loss (see page 10). ZURICH saw declines of 4.1% and 1.1%, respectively, for drug majors Roche and Novartis, while Speedel gained 2.8% on no particular news since its downgrade last month by JP Morgan analysts.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
Become a subscriber
£820
Or £77 per month
Chairman, Sanofi Aventis UK
Company News Directory
Companies featured in this story
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Company Spotlight
| Headless Content Management with Blaze